Skip to main content

Non-nucleotide Modification of Anti-miRNA Oligonucleotides

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1517))

Abstract

MicroRNAs (miRNAs) are important modulators of gene expression. Synthetic anti-microRNA oligonucleotides (AMOs, or anti-miRs) are a form of steric-blocking antisense oligonucleotides (ASOs) that inhibit miRNA function through high-affinity binding and subsequent inactivation and/or degradation of the targeted miRNA. AMOs are a primary tool used to empirically determine the biological targets of a miRNA and can also be used therapeutically when overexpression of a miRNA contributes to a disease state. Chemical modification of synthetic AMOs enhance potency by protecting the oligonucleotide from nuclease degradation and by increasing binding affinity to the target miRNA. A new steric-blocking ASO modification strategy with favorable properties for use in AMOs was recently developed that combines use of high-affinity 2′-O-methyl RNA with terminally positioned non-nucleotide “ZEN” modifiers. This protocol describes use of ZEN AMOs in a dual-luciferase reporter assay as a simplified means to validate AMO performance or to quickly test putative miRNA binding sites in target sequences. This protocol also describes a method using Western blot analysis for quantifying the level of upregulation of proteins made from an mRNA that is thought to be under miRNA regulation, following inhibition of that miRNA by ZEN AMO treatment.

This is a preview of subscription content, log in via an institution.

Buying options

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297

    Article  CAS  PubMed  Google Scholar 

  2. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854

    Article  CAS  PubMed  Google Scholar 

  3. Li Y, Kowdley KV (2012) MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics 10:246–253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Trionfini P, Benigni A, Remuzzi G (2015) MicroRNAs in kidney physiology and disease. Nat Rev Nephrol 11:23–33

    Article  CAS  PubMed  Google Scholar 

  5. Meola N, Gennarino VA, Banfi S (2009) MicroRNAs and genetic diseases. Pathogenetics 2:7

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15:509–524

    Article  CAS  PubMed  Google Scholar 

  7. Carthew RW, Sontheimer EJ (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136:642–655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lima WF, Wu H, Crooke ST (2008) Antisense drug technology, principles, strategies, and applications, vol 2. CRC Press, Boca Raton, FL, pp 47–74

    Google Scholar 

  9. Baskerville S, Bartel DP (2005) Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 11:241–247

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Vickers TA, Wyatt JR, Freier SM (2000) Effects of RNA secondary structure on cellular antisense activity. Nucleic Acids Res 28:1340–1347

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lennox KA, Behlke MA (2011) Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther 18:1111–1120

    Article  CAS  PubMed  Google Scholar 

  12. Lennox KA, Behlke MA (2010) A direct comparison of anti-microRNA oligonucleotide potency. Pharm Res 27:1788–1799

    Article  CAS  PubMed  Google Scholar 

  13. Lennox KA, Owczarzy R, Thomas DM, Walder JA, Behlke MA (2013) Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier. Mol Ther Nucleic Acids 2:e117

    Article  PubMed  PubMed Central  Google Scholar 

  14. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685

    Article  CAS  PubMed  Google Scholar 

  15. Graham DR, Garnham CP, Fu Q, Robbins J, Van Eyk JE (2005) Improvements in two-dimensional gel electrophoresis by utilizing a low cost "in-house" neutral pH sodium dodecyl sulfate-polyacrylamide gel electrophoresis system. Proteomics 5:2309–2314

    Article  CAS  PubMed  Google Scholar 

  16. Zhou JY, Ma WL, Liang S, Zeng Y, Shi R, Yu HL, Xiao WW, Zheng WL (2009) Analysis of microRNA expression profiles during the cell cycle in synchronized HeLa cells. BMB Rep 42:593–598

    Article  CAS  PubMed  Google Scholar 

  17. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647–658

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH (2010) MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 411:846–852

    Article  CAS  PubMed  Google Scholar 

  19. Li T, Li D, Sha J, Sun P, Huang Y (2009) MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383:280–285

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Garrett Rettig for critical reading of the chapter and Todd Adamson for assistance in preparing Fig. 2.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark A. Behlke .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this protocol

Cite this protocol

Lennox, K.A., Vakulskas, C.A., Behlke, M.A. (2017). Non-nucleotide Modification of Anti-miRNA Oligonucleotides. In: Schmidt, M. (eds) Drug Target miRNA. Methods in Molecular Biology, vol 1517. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6563-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6563-2_3

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6561-8

  • Online ISBN: 978-1-4939-6563-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics